DK2280734T3 - Faktor-ix-konjugater med forlængede halveringstider - Google Patents

Faktor-ix-konjugater med forlængede halveringstider

Info

Publication number
DK2280734T3
DK2280734T3 DK09734192.9T DK09734192T DK2280734T3 DK 2280734 T3 DK2280734 T3 DK 2280734T3 DK 09734192 T DK09734192 T DK 09734192T DK 2280734 T3 DK2280734 T3 DK 2280734T3
Authority
DK
Denmark
Prior art keywords
conjugates
factor
half times
extended half
extended
Prior art date
Application number
DK09734192.9T
Other languages
Danish (da)
English (en)
Inventor
William Henry
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Application granted granted Critical
Publication of DK2280734T3 publication Critical patent/DK2280734T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK09734192.9T 2008-04-24 2009-04-24 Faktor-ix-konjugater med forlængede halveringstider DK2280734T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4754408P 2008-04-24 2008-04-24
PCT/IB2009/005763 WO2009130602A2 (en) 2008-04-24 2009-04-24 Factor ix conjugates with extended half-lives

Publications (1)

Publication Number Publication Date
DK2280734T3 true DK2280734T3 (da) 2014-05-26

Family

ID=41171051

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09734192.9T DK2280734T3 (da) 2008-04-24 2009-04-24 Faktor-ix-konjugater med forlængede halveringstider

Country Status (22)

Country Link
US (1) US20110183906A1 (enExample)
EP (1) EP2280734B1 (enExample)
JP (1) JP2011519833A (enExample)
KR (1) KR20110016440A (enExample)
CN (1) CN102046205A (enExample)
AU (1) AU2009239641B2 (enExample)
BR (1) BRPI0911350A2 (enExample)
CA (1) CA2722169A1 (enExample)
CO (1) CO6300965A2 (enExample)
CR (1) CR11763A (enExample)
DK (1) DK2280734T3 (enExample)
EC (1) ECSP10010632A (enExample)
ES (1) ES2466340T3 (enExample)
IL (1) IL208908A0 (enExample)
MX (1) MX2010011672A (enExample)
MY (1) MY158228A (enExample)
NI (1) NI201000177A (enExample)
NZ (1) NZ588854A (enExample)
RU (1) RU2496521C2 (enExample)
UA (1) UA101497C2 (enExample)
WO (1) WO2009130602A2 (enExample)
ZA (1) ZA201007559B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0720282B8 (pt) 2006-12-15 2021-05-25 Baxalta GmbH construção proteica, composição farmacêutica, e, kit
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN104530182A (zh) 2009-07-27 2015-04-22 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
HRP20160916T1 (hr) 2009-07-27 2016-11-18 Baxalta GmbH Konjugati proteina za koagulaciju krvi
US9795683B2 (en) 2009-07-27 2017-10-24 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CA2770609A1 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
AU2011274414B2 (en) * 2010-07-09 2016-10-06 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
SG191298A1 (en) 2010-12-22 2013-07-31 Baxter Int Materials and methods for conjugating a water soluble fatty acid derivative to a protein
EP3412314A1 (en) * 2011-05-27 2018-12-12 Baxalta GmbH Therapeutic proteins conjugated to polysialic acid and methods of preparing same
WO2013156488A2 (en) * 2012-04-16 2013-10-24 Leverton Licence Holdings Limited Optimised subcutaneous therapeutic agents
US20150125473A1 (en) * 2012-06-19 2015-05-07 Polytherics Limited Novel process for preparation of antibody conjugates and novel antibody conjugates
HK1213521A1 (zh) 2012-09-25 2016-07-08 Bioverativ Therapeutics Inc. Fix多肽的應用
TWI745671B (zh) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 因子ix多肽調配物
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
EA038573B1 (ru) 2014-03-24 2021-09-16 Биовератив Терапьютикс Инк. Лиофилизированный состав, содержащий фактор ix, для предупреждения приступов кровотечения
GB2564389A (en) 2017-07-04 2019-01-16 Green Running Ltd A system and method for utility management

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
JP2003521930A (ja) * 2000-02-11 2003-07-22 マキシゲン・エイピーエス 第VII因子または第VIIa因子様分子
WO2004060965A2 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
ATE399185T1 (de) * 2002-12-31 2008-07-15 Nektar Therapeutics Al Corp Maleinsäureamid polymerderivate und ihre biokonjugate
EP1581582B2 (en) * 2003-01-06 2017-06-07 Nektar Therapeutics Thiol-selective water-soluble polmer derivatives
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
PL1842920T5 (pl) 2003-09-23 2018-04-30 University Of North Carolina At Chapel Hill Komórki koekspresjonujące reduktazę witaminy K i białko zależne od witaminy K oraz ich zastosowanie do poprawienia wydajności wytwarzania tego białka zależnego od witaminy K
JP4855074B2 (ja) * 2003-09-30 2012-01-18 一般財団法人化学及血清療法研究所 高純度血液凝固ix因子調製物およびその精製方法
DE602004026897D1 (de) 2003-10-14 2010-06-10 Baxter Healthcare Sa Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
ES2390082T5 (es) * 2004-06-30 2018-01-19 Nektar Therapeutics Conjugados de resto de Factor IX y polímeros
WO2006063292A1 (en) 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
EP2295547B1 (en) 2005-02-28 2017-09-20 Baxalta GmbH Recombinant co-expression of vitamin K epoxide reductase subunit 1 to improve vitamin K dependant protein expression
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
JP5216580B2 (ja) * 2005-05-25 2013-06-19 ノヴォ ノルディスク アー/エス グリコペグ化第ix因子
MX2008012600A (es) * 2006-03-31 2008-12-12 Baxter Int Factor viii pegilado.
EP2213733A3 (en) * 2006-05-24 2010-12-29 Novo Nordisk Health Care AG Factor IX analogues having prolonged in vivo half life
JP5737821B2 (ja) * 2006-08-17 2015-06-17 一夫 大橋 血友病b治療剤及びその製造方法

Also Published As

Publication number Publication date
BRPI0911350A2 (pt) 2017-12-05
UA101497C2 (ru) 2013-04-10
WO2009130602A3 (en) 2010-02-11
MX2010011672A (es) 2011-03-02
CO6300965A2 (es) 2011-07-21
HK1151986A1 (en) 2012-02-17
US20110183906A1 (en) 2011-07-28
RU2010147813A (ru) 2012-05-27
WO2009130602A9 (en) 2010-04-22
ZA201007559B (en) 2012-01-25
AU2009239641A1 (en) 2009-10-29
JP2011519833A (ja) 2011-07-14
AU2009239641B2 (en) 2013-11-07
ES2466340T3 (es) 2014-06-10
WO2009130602A2 (en) 2009-10-29
RU2496521C2 (ru) 2013-10-27
MY158228A (en) 2016-09-15
IL208908A0 (en) 2011-01-31
ECSP10010632A (es) 2011-02-28
EP2280734B1 (en) 2014-02-26
CA2722169A1 (en) 2009-10-29
CN102046205A (zh) 2011-05-04
NI201000177A (es) 2011-08-29
NZ588854A (en) 2011-12-22
KR20110016440A (ko) 2011-02-17
CR11763A (es) 2011-04-26
EP2280734A2 (en) 2011-02-09

Similar Documents

Publication Publication Date Title
FIC20240020I1 (fi) Atetsolitsumabi
DK2280734T3 (da) Faktor-ix-konjugater med forlængede halveringstider
DK2308877T3 (da) Imidazopyridin-2-on-derivater
DK2370462T3 (da) Glucagon-analoger
DK2342317T3 (da) Hængende-dråbe-plade
DE602009000234D1 (de) msignals
BRPI0907376A2 (pt) Fotobiorretador
DK3444343T3 (da) Polypeptider
BRPI0918823A2 (pt) beta-glicosidases modificadas com estabilidades aperfeicoada
DK2373293T3 (da) Sammensætninger med reduceret dimerdannelse
EP2329802A4 (en) EMBEDDED AUDIOPHONE
DE602008003972D1 (de) Sitzrücklehnungsmechanismus
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
DK2342454T3 (da) Vindkraftanlæg
DK2335031T3 (da) In-line-måler
DK2336132T3 (da) Morpholinpurinderivat
DK2275414T3 (da) Cyclopentylacrylamidderivat
DK2379557T3 (da) Aminopyrazol-forbindelse
DK2271613T3 (da) Hydroxymethylcyklohexylaminer
DE602008003970D1 (de) Strahlstromkalibriersystem
BRPI0907522A2 (pt) biarlamidas
ATE534634T1 (de) 2-phenyl-4-cyclopropyl-pyrimidinderivate
BRPI0909634A2 (pt) 2-aminoquinolinas
DE602009000862D1 (de) Gehwagenbremse
DK2380892T3 (da) Imidazothiazolderivat med prolinringstruktur